WO2014013090A3 - Formulation comprenant du fingolimod amorphe - Google Patents
Formulation comprenant du fingolimod amorphe Download PDFInfo
- Publication number
- WO2014013090A3 WO2014013090A3 PCT/EP2013/073902 EP2013073902W WO2014013090A3 WO 2014013090 A3 WO2014013090 A3 WO 2014013090A3 EP 2013073902 W EP2013073902 W EP 2013073902W WO 2014013090 A3 WO2014013090 A3 WO 2014013090A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fingolimod
- formulation
- amorphous
- pharmaceutical formulation
- composite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
La présente invention concerne un composite solide contenant une base de fingolimod et un copolymère d'acide méthacrylique et de divinylbenzène, une formulation pharmaceutique comprenant ledit composite, et l'utilisation du composite solide ou de la formulation pharmaceutique en tant que médicament, en particulier pour le traitement de la sclérose en plaques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2013/059370 | 2013-05-06 | ||
EP2013059370 | 2013-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014013090A2 WO2014013090A2 (fr) | 2014-01-23 |
WO2014013090A3 true WO2014013090A3 (fr) | 2014-04-03 |
Family
ID=49622811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/073902 WO2014013090A2 (fr) | 2013-05-06 | 2013-11-15 | Formulation comprenant du fingolimod amorphe |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014013090A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015131034A (ru) * | 2013-01-15 | 2017-02-01 | Сан Фармасьютикал Индастрис Лтд. | Устойчивая композиция, содержащая финголимод |
WO2016042493A1 (fr) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Compositions pharmaceutiques de fingolimod |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008037421A2 (fr) * | 2006-09-26 | 2008-04-03 | Novartis Ag | Composés organiques |
EP2198857A1 (fr) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Comprimé dispersible oral |
EP2505589A1 (fr) * | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations |
-
2013
- 2013-11-15 WO PCT/EP2013/073902 patent/WO2014013090A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008037421A2 (fr) * | 2006-09-26 | 2008-04-03 | Novartis Ag | Composés organiques |
EP2198857A1 (fr) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Comprimé dispersible oral |
EP2505589A1 (fr) * | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
WO2014013090A2 (fr) | 2014-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016011222A3 (fr) | Polynucléotides circulaires | |
WO2014205389A8 (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
CA2894892A1 (fr) | Derives d'acide boronique et leurs utilisations therapeutiques | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
WO2015077503A8 (fr) | Composés inhibiteurs de l'autotaxine | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
WO2013170068A3 (fr) | Modulateurs du transport nucléaire et leurs utilisations | |
CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
WO2014096425A3 (fr) | Promédicaments de fumarate de monométhyle (mmf) | |
WO2015056094A3 (fr) | Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique | |
WO2011141488A3 (fr) | Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone | |
WO2013003669A3 (fr) | Compositions, méthodes d'utilisation et méthodes de traitement | |
MX340188B (es) | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
WO2012162439A3 (fr) | Compositions comprenant de l'acide fusidique et leurs emballages | |
CA2863376A1 (fr) | Comprimes gastro-resistants | |
WO2014203275A3 (fr) | Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires | |
WO2014121137A3 (fr) | Compositions et méthodes utilisables en vue du traitement de maladies neurodégénératives et autres | |
WO2014106825A3 (fr) | Procédés et dispositifs d'identification de notification médicale erronée | |
WO2016001937A3 (fr) | Formulations pharmaceutiques à libération modifiée | |
WO2014033526A9 (fr) | Compositions pharmaceutiques d'étoricoxib | |
WO2015082590A3 (fr) | Dérivés de bis-mmf | |
EP3530654A4 (fr) | Composé d'acide carboxylique à substitution quinolinyle ou sel pharmaceutiquement acceptable de celui-ci, composition pharmaceutique et utilisation associées | |
WO2014125504A3 (fr) | Compositions pharmaceutiques de fébuxostat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13792896 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13792896 Country of ref document: EP Kind code of ref document: A2 |